EVO NASDAQ Week ended 07 Aug 2026

Weekly Investor Report

Evotec SE ADR · Healthcare · Drug Manufacturers - Specialty & Generic

Open interactive chart View report data
Latest close 2.00 USD
4.7% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -30.2% below the Trend Line and sits at 4.4% of its 52-week range. The latest completed week returned 4.7%, after a -28.2% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 45/100.

Setup score 19 out of 100
Latest Close 2.00 USD 7 Aug 2026
1W Return 4.7% latest completed week
4W Return -28.2% short-term follow-through
12W Return -25.9% quarterly tape
Trend Breadth 0.0% 0 of 52 weeks active
Volume Ratio 2.5x vs 13-week average
What is working
  • Volume is elevated versus the 13-week average, confirming attention.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 4.7% Latest completed week; four-week move -28.2%. Indicator stack 0/0 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Recent Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 41.43% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 45/100 19 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -30.2% below the Trend Line and sits at 4.4% of its 52-week range. The latest completed week returned 4.7%, after a -28.2% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 2.5x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul 7 Aug
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0312-week average 0.06

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure5/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.03Current proprietary activity-pressure read.
Buy signals1Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -28.2% over four weeks, -25.9% over 12 weeks, and -49.1% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W4.7%
4W-28.2%
12W-25.9%
26W-43.3%
52W-49.1%
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.98Latest activity-pressure read.
Pressure change-643.0%Four-week change in activity pressure.
Leadership-44.45Latest relative-leadership reading.
RS change-59.0%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 09 Aug 2026 Financial statements through 31 Mar 2026 Field coverage 88% Model confidence 82%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength29/100Blend of value, momentum, and quality. Underlying universe rank 72; rank 1 is best.
Value73/100Relative valuation strength. Underlying universe rank 28; rank 1 is best.
Quality10/100Profitability and accounting quality. Underlying universe rank 91; rank 1 is best.
Momentum5/100Medium-term price momentum. Underlying universe rank 96; rank 1 is best.
Growth19/100Revenue and earnings growth. Underlying universe rank 82; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
1.0x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
12.0%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
11.4%
Gross profit retained from each unit of revenue.
Operating margin
-20.9%
Operating profit retained from revenue.
Free-cash-flow margin
11.4%
Free cash flow generated from revenue.
Return on invested capital
-16.7%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-5.2%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-41.5%
Latest one-year free-cash-flow growth.
Piotroski F-score
5/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
0.0%
Cash dividends relative to market value.
Buyback yield
0.2%
Net share repurchases relative to market value.
Shareholder yield
0.2%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.0x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment45/100

Weighted news tone is neutral across 19 relevant articles.

1 positive · 13 neutral · 5 negative
Patient CapitalRecent

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

Recent buy signal in the last 8 weeks
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-53.2%Distance below the 52-week high.
13-week volatility10.1%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher10 of 2616 weeks finished lower.
Best week+24.0%Week of 17 Apr.
Worst week-29.6%Week of 17 Jul.
Latest week+4.7%Week of 7 Aug.

Shape of recent returns

Strong gains7
Modest gains3
Flat weeks0
Modest losses10
Sharp losses6
Recent vol10.1%13-week weekly-return volatility.
Base vol9.0%52-week weekly-return volatility.
Up/down split19/32Count of positive and negative weeks in the 52-week window.
Average skew6.9% / -5.5%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape18/100

Trend, activity pressure, participation, and risk combine to a 18/100 tape read.

 Indicator analysis18/100

Latest 12-week confirmation: trend 0/12, activity pressure 5/12, relative leadership 0/12.

Activity pressure 0.03; No reversal markers Next-Week ExpectancyNegative 41.43%

Next-week expectancy is negative with a 41.43% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors28/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 39; Small Cap Core rank 65 Patient CapitalRecent

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

Recent buy signal in the last 8 weeks Sentiment45/100

Weighted news tone is neutral across 19 relevant articles.

EVO|Evotec SE|Price:1.930|Chg%:-0.030 Insiders50/100

No recent insider transaction evidence is stored.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
7 Aug 20262.00 USD4.7%2.87 USD4.97 USD-0.98-44.45666.3KOff
31 Jul 20261.91 USD-1.5%2.92 USD5.04 USD-0.77-45.12307.7KOff
24 Jul 20261.94 USD-1.0%2.96 USD5.11 USD-0.39-44.89216.2KOff
17 Jul 20261.96 USD-29.6%3.00 USD5.17 USD-0.01-46.16662.6KOff
10 Jul 20262.79 USD-4.0%3.04 USD5.25 USD0.18-27.96124.0KOff
3 Jul 20262.90 USD5.8%3.04 USD5.31 USD0.20-24.58145.6KOff
26 Jun 20262.74 USD7.0%3.05 USD5.36 USD0.12-29.02156.1KOff
19 Jun 20262.56 USD-5.9%3.07 USD5.42 USD0.10-37.49212.6KOff
12 Jun 20262.72 USD-2.9%3.08 USD5.47 USD0.05-32.67161.1KOff
5 Jun 20262.80 USD-8.8%3.09 USD5.53 USD-0.11-30.14149.7KOff
29 May 20263.07 USD1.3%3.10 USD5.59 USD-0.18-27.7694.5KOff
22 May 20263.03 USD12.2%3.14 USD5.65 USD-0.30-27.49191.7KOff
15 May 20262.70 USD-12.1%3.17 USD5.70 USD-0.24-35.68412.1KOff
8 May 20263.07 USD-0.6%3.21 USD5.75 USD-0.20-28.04390.6KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.

Evidence context